Introduction
The external envelope glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1) is heavily glycosylated and can show variation of 25% in amino acid sequence between different isolates of the virus (Desai et al., 1986) . Two separate, putative cysteine loops within the nine disulphide bonds reported for the molecule (Fennie & Lasky, 1989) contain the CD4-binding region (Lasky et al., 1987) , by which the virus binds to its cellular receptor, and the immunodominant neutralizing epitope (Javaherian et al., 1989; Meloen et al., 1989) .
The carbohydrate moieties may play a role in determining the outcome of infection by preventing antibody binding to potentially neutralizing epitopes or acting as decoys by inducing non-neutralizing antibodies (Alexander & Elder, 1984) . As far as HIV-1 gpl20 is concerned, carbohydrate is not essential for the induction of neutralizing antibodies in experimental animals because enzymically deglycosylated gp 120 (Putney et al., 1986) and recombinant gpl20 produced in bacteria (Putney et al., 1986) or yeast (Steimer et al., 1987) , which 0000-9658 © 1990 SGM lack carbohydrate, are able to induce strain-specific neutralizing antibodies.
There is as yet no consensus on whether carbohydrate is essential for gpl20 to bind to the CD4 receptor. Matthews et al. (1987) showed a 50-fold reduction in gpl20 binding to the CD4 receptor following enzymic deglycosylation. However, Fenouillet et al. (1989) , by avoiding the use of SDS in the enzyme diluent, were able to show binding of deglycosylated gp120 to both soluble and cell-associated CD4 with only a twofold reduction in binding in comparison to the native molecule.
The variation in amino acid sequence is not uniformly distributed along the length of the gpl20 molecule (Alizon et al., 1986; Starcich et al., 1986; Willey et al., 1986) ; the molecule can be divided into conserved and variable regions. Within the variable regions there are 'hot' spots of increased variation associated with insertions or deletions of short directly repeated sequences of amino acids (Alizon et al., 1986; Sauermann et al., 1990) . These 'hot' spots are rich in asparagine residues, many of which form putative glycosylation sites. Since the variation in amino acid sequence is highest within these regions, the putative glycosylation sites also show variation in number and position, both between strains of the virus from different patients and from variants separated over time from the same patient . Furthermore, these regions show variation in their predicted secondary structures between isolates from the same patient and are predicted to be B cell epitopes (Modrow et al., 1987) . They must therefore be considered as candidates for the neutralizing epitopes involved in producing variant viruses within an individual patient if HIV-1 has a pathogenesis similar to that of the equine and ovine lentiviruses (Montelaro et al., 1986; Narayan et al., 1986).
The present study was undertaken to raise antibodies to an overlapping series of peptides representing the entire sequence of gpl20, and to investigate their antiviral properties. The availability of recombinant gpl20, both glycosylated and unglycosylated, permitted an investigation of the epitopes which bind antibodies and whether carbohydrate can block this binding, irrespective of any effect on viral infectivity.
Methods
Peptides and conjugates. The amino acid sequences of the peptides follow that published by Sanchez-Pescador et al. (1985) , starting at residue 1 of gp 120. The peptides have 15 amino acids of the published sequence and overlap by five amino acids. Thus, peptide env 1 has the sequence corresponding to amino acids 1 to 15, peptide env 2 the sequence 11 to 25, peptide env 3 21 to 35, and so on to give peptide env 52 the sequence 511 to 525, which includes the putative C terminus of the gpl20 molecule. An additional cysteine has been added to the C terminus of most of the peptides to enable conjugation to a carrier protein. Peptides env 4, 6, 8, 13, 14, 16, 17, 22, 24, 25, 26, 31, 34, 42, 43 and 45 have internal cysteines so a tyrosine is used as the additional amino acid. Either the N or the C terminus of peptides env 3, 7, 9, 35 and 39 coincides with a cysteine residue and peptides env 21, 23 and 40 contain both a cysteine and tyrosine residue so no additional residue was added to any of these peptides (Table 1) . The peptides were synthesized by the 9-fluorenylmethoxycarbonyl (FMOC)-polyamide method (see below). Peptides (5 mg) were retained by the manufacturers (Cambridge Research Biochemicals) for conjugation to purified protein-derivative (PPD), either through the terminal cysteine residue using m-maleimidobenzoic acid N-hydroxysuccinimide ester or the terminal tyrosine residue using bis-diazotized toluidine, or in the case of env 21, 23, 39 and 40, using glutaraldehyde.
Injection schedules. F1 AO × LOU hybrid rats were injected with Bacille-Calmette-Guerin and peptide conjugated to PPD, according to the schedule previously described (Davis et al., 1990) .
Recombinant antigens. The following reagents were obtained through the AIDS Research and Reference Reagent Program, AIDS Program, NIAID, NIH : glycosylated gp 120 (CHO-cell derived) from HIV-SF2 from Dr N. L. Haigwood of Chiton Corporation (Levy et al., 1984; Sanchez-Pescador et al., 1985; Haigwood et al., 1990) and nonglycosylated gpl20 (yeast-derived) from HIV-SF2 from Dr K. S. Steimer of Chiron Corporation (Steimer et al., 1988; Haigwood et al., 1990) . The following reagents were obtained through the Medical Research Council AIDS Directed Programme: glycosylated gpl20 (CHO-cell derived) from HIV-BH10 (Ratner et al., 1985) from Celltech and glycosylated gpl20 (baculovirus-derived) from American Biotechnologies.
Solid-phase radioimmunoassay. Peptides and recombinant proteins were used as solid phase in a radioimmunoassay as previously described (Davis et aL, 1990 ). Antipeptide sera were tested against recombinant proteins in batches. Batches 1, 2 and 3 were antisera to peptides env 5 to 52, excluding env 13 and env 36, which gave the highest titre of anti-peptide activity, i.e. sera represented in columns 1, 2 and 3 of Table 2 . Batch 4 included sera to peptides env 13 and 26, corresponding to column 4 in Table 2 . The remaining sera were tested in batch 5. Pools of normal rat sera were included in each assay. Results are presented quantitatively as antibody bound to antigen along the length of gpl20 cumulated over the first three batches of sera. For baculovirus-derived antigen, only the results from batch 4 sera are presented because of doubts concerning the results obtained with the first three batches, which may reflect a deterioration of the antigen following storage at -70 °C. All sera were also scored qualitatively. Antipeptide sera were considered to bind to recombinant proteins if they gave twice the level of antibody binding to antigen as was seen with pooled normal rat sera.
Epitope mapping with hexamers. Solid-phase peptide chemistry was carried out in collaboration with Cambridge Research Biochemicals using the FMOC-polyamide mode of synthesis (Atherton et al., 1981) . The insoluble support used for peptide synthesis was polyacrylic acidcoated polyethylene rods (Geysen et aL, 1987) .
The external glycoprotein of HIV-SF2 was synthesized in duplicate as overlapping hexapeptides, covalently bound to the insoluble support. The first peptide synthesized represented residues 1 to 6 (from the N terminus), the second 2 to 7 and so on, until the entire sequence of gp 120 had been obtained. Synthesis was achieved by successive cycles of FMOC deprotection and addition of one amino acid per day to obtain peptides of the desired length. A microcomputer program (Cambridge Research Biochemicals) was used to direct the addition of the correct amino acid. Upon completion of the final coupling reaction, and following removal of the FMOC protecting group, the N-terminal amino group was acetylated to remove the abnormal charge associated with the nitrogen atom. The completed hexapeptides were then sidechain deprotected by treatment in a cleavage mixture containing trifluoroacetic acid, phenol and ethanedithiol (95:2-5:2-5, v :w :v).
The peptides, bound to the rods, were ultrasonicated to form the lowest energy configuration of their final form. In addition, after use antibodies were removed from the peptides before the latter were used again. These two conditions were achieved by sonicating the peptides on the rods in a solution containing SDS (1 ~ w/v), 2-mercaptoethanol (0.1 ~ v/v) and sodium phosphate (0.1 M pH 7.2) prewarmed to 60 °C. They were then washed in water at 60 °C, then in boiling methanol, and allowed to dry in air.
The hexapeptides, covalently bound to their rods, were submerged in phosphate-buffered saline, with 2 mg/ml bovine serum albumin, 0.05 Tween 20 and 10 mM-azide, and incubated for 4 h at room temperature in a water-saturated atmosphere on a rocking table to block nonspecific antibody binding. The hexapeptides were transferred to wells containing 1:100 dilutions of antipeptide antibody, incubated overnight at 4 °C on a rocking table, washed, transferred to wells containing peroxidase-conjugated anti-rat IgG (Sigma) and incubated at room temperature for 4 h. The presence of enzyme on the rods was detected by transferring them to wells containing 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS; Sigma). Colour development could be stopped simultaneously in all wells by removing the rods from the ABTS. Absorbance was measured at 405 nm. One of the rat antipeptide sera for each peptide was examined in this assay and absorbances greater than 1.0 unit were considered significant. Human sera. Sera were obtained from HIV-1 seropositive patients and healthy laboratory personnel as previously described (Davis et al., 1990) .
Peptides recognized by human antibodies. Human sera were used in radioimmunoassays (see above) using peptides as the solid phase as previously described (Davis et al., 1990) . Qualitative scoring of sera against each peptide involved ranking the antibody levels bound to each peptide and noting the twelfth lowest value, i.e. the value with the lowest 25~ values below it. Any serum/peptide combination that showed binding at greater than twice the twelfth value was considered positive. This method is adapted from Geysen et al. (1987) .
Computer analysis. The amino acid sequence of HIV-SF2 gpl20 was analysed using the program of Hopp & Woods (1981) . Table 2 and distinguished by different shadings) of rat antipeptide sera against glycosylated recombinant gpl20 from HIV-1 of a heterologous strain, HIV-BHI0 (a), or the homologous strain, HIV-SF2 (c). A hydrophilicity plot of the HIV-SF2 gp120 amino acid sequence is shown (b). Putative glycosylation sites are marked by vertical lines for each recombinant gpl20. Cumulative totals of antibody determination by radioimmunoassay are displayed.
Results

Epitopes of glycosyla ted gp 120
The antipeptide sera that showed the highest level of binding to glycosylated recombinant gpl20 corresponded to peptides which fell into five groups (Fig. 1 a) :
peptides env 9, 10, 11 and 12 (amino acids 81 to 125), env 18 and 19 (171 to 195), env 23 (221 to 235), env 32 and 33 (311 to 335) and env 48 (471 to 485). Antisera from three of these groups, peptides env 9 to 12, env 23 and env 48, also show high levels of antibody to glycosylated gpl20 from HIV-BH10 (Fig. l c) . No unified hypothesis gives an explanation which can be accepted for all of the antibody-binding regions. One hypothesis is that antibody binds to those parts which are exposed on the surface of the molecule. However, a hydrophilicity plot (Fig. 1 b) indicated that peptides env 18 and 48 correspond to hydrophilic regions of gpl20 and peptides env 10 and 23 to hydrophobic regions.
Epitopes of HIV-1 gp120
Anti-15-mer peptide titres
A second hypothesis is that the pattern of binding to recombinant gpl20 reflects the concentration of antibody in the serum. The antisera were therefore titrated against their respective peptides (Table 2 ). All the Table 2 and distinguished by different shadings) of rat antipeptide sera against unglycosylated recombinant gpl20 from HIV-1 of the homologous strain, HIV-SF2. Cumulative totals of antibody determination by radioimmunoassay are displayed.
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antisera which showed high levels of binding to the glycosylated recombinant gpl20 also showed high titres (1:750 or greater) to their peptides, except for those raised against env 18 and env 23 (titre of 1:150). However, there were also antisera which showed high titres against their peptides and low levels of binding to the recombinant molecule.
Anti-hexapeptide activity
Antisera that recognize multiple epitopes within their corresponding amino acid sequence may show higher binding to the recombinant molecule than those antisera which only recognize a single epitope. Antisera raised to peptides env 1, 2, 7, 17, 18, 21, 32, 33, 34, 35, 38, 39, 41, 42, 44, 46, 47, 48, 49 and 51 can bind to more than one hexapeptide within the 15 amino acid sequence to which they were induced (Fig. 2) . Peptides env 5, 20, 23, 31 and 50 recognized a single hexamer and the remaining L antisera failed to recognize any hexamers. Thus, amongst the antisera that bound at high levels to recombinant gpl20, those raised to peptides env 9, 10, 12 and 19 failed to bind to hexamers.
Glycosylation pattern
The regions of HIV-SF2 gp 120 which are free of putative glycosylation sites (amino acids 38 to 94, 96 to 136, 167 to 191,207 to 230, 313 to 341,417 to 452 and 467 to 517) correspond to the regions of the molecule which bind high levels of antipeptide antibody (Fig. 1). The regions   20000   i,, ,,,, ,, ,, ,,, ,, , Peptide number Fig. 4 . Activity of batch 4 (see Table 2 ) of rat antipeptide sera against baculovirus-derived glycosylated recombinant gpl20 from HIV of a heterologous strain, HIV-BH10. Histograms of antibody determination by radioimmunoassay are displayed.
corresponding to peptides env 10, 19 and 32 contain putative glycosylation sites, but there are long stretches of amino acids adjacent to these sites which may be available to bind antibody. The glycosylation sites corresponding to env 10, 19 and 32 are immediately adjacent to stretches of 40, 25 and 29 amino acids respectively which are free of putative glycosylation sites. Finally, antibodies raised to peptides will recognize linear sequences of amino acids rather than conformational determinants, so that only those regions of the recombinant molecule where linear epitopes are available on the surface will be able to bind such antibodies. This hypothesis was not addressed in this study.
Epitopes of unglycosylated gp l 20
To test whether carbohydrate was preventing antibody binding to gpl20, supplies of recombinant unglycosylated gpl20 produced in yeast were obtained. The absence of carbohydrate from HIV-SF2 gpl20 revealed five regions of the molecule which were able to bind high levels of antibody in addition to those already observed with the glycosylated molecule (Fig. 3) . Those regions were amino acids 61 to 75 (no glycosylation site), 131 to 145 (one glycosylation site), 161 to 175 (two glycosylation sites), 301 to 315 (two glycosytation sites) and 401 to 415 (two glycosylation sites).
Epitopes of baculovirus-derived gp l 20
Recombinant gpl20 from the BH10 strain of HIV-1 produced in insect cells showed the same pattern of epitopes as recombinant BH10 gpl20 from mammalian cells (Fig. 4) 10 and env 12, and env 23 and env 48 showed the highest level of antibody binding. However, when these assays were repeated using material stored at -70 °C, no peak of antibody-binding activity was observed with antisera raised to peptide env 23 (data not shown). This observation may indicate a problem of storage with this molecule, although antibodies to peptides env 9, 10, 11, 12 and 48 bound at high levels to the recombinant molecule following storage.
Qualitative analysis of gp l 20 epitopes
Examination of Fig. 1, 3 and 4 reveals that a number of peptide conjugates induced antibody which bound to recombinant gpl20 but at lower levels than those showing the highest binding activity. Any level of binding indicates that an epitope is accessible to antibody; Table 1 compares the binding to recombinant molecules with that to pooled normal rat sera.
Peptides which bind antibody from HIV-l-infected patients" sera
The pattern of antibody binding to the overlapping series of peptides from gpl20 was similar across the entire length of the molecule whether sera were obtained from HIV seropositive individuals or laboratory personnel (Fig. 5) . Since the binding of antibodies in normal human serum is considered to be specific, albeit induced by immunogens unrelated tO HIV-1 (Davis et al., 1990) , data obtained with sera from HIV-infected patients have been presented without subtracting values obtained from normal sera. The peptides which bound the highest levels of antibodies from the sera of HIV seropositive individuals were env 17, 24 and 32. The highest levels of binding of antibodies from the sera of laboratory personnel were seen with peptides env 12, 17 and 24. When the peptides were ranked with respect to the level of antibody binding within a single serum, the peptides showing activity of twice that observed with the twelfth lowest peptide were considered to bind significant levels of antibody and are recorded in Table 1 .
Discussion
There are five major epitopes on recombinant HIV-1 gpl20 which are sequestered beneath carbohydrate. These epitopes can be demonstrated, using antibodies raised to peptides, on gpl20 which is lacking carbohydrate but not on glycosylated gp 120 with the same amino acid sequence. The epitope (amino acids 61 to 75) nearest the N terminus of the molecule lies within a conserved region and does not contain any putative glycosylation sites.
The second epitope (amino acids 131 to 145) is in the first variable region, as defined by Modrow et al. (1987) , where sequences show evidence of duplication over stretches of between three and five amino acids (Alizon et al., 1986) . Since this region also contains putative glycosylation sites, these are also duplicated and can form clusters in some strains of HIV-1. There is one putative glycosylation site at residue 136 contained in the amino acid sequence represented by env 14 in HIV-SF2. This site is next to a cysteine residue which is conserved in all HIV-1 strains, although the adjacent asparagine, threonine or serine residues have been substituted in some strains. There is a second site at amino acid position 143 (lysine) in other strains of HIV-1. The third epitope (amino acids 161 to 175) is within the second variable region of gpl20 and contains two putative glycosylation sites at amino acid positions 162 and 166. The asparagine-cysteine-serine sequence of the first site is conserved in all strains of the virus, whereas the asparagine at amino acid position 166 has been substituted in some strains of HIV-1
The fourth epitope (amino acids 301 to 315) contains two putative glycosylation sites (at amino acids 306 and 312) and lies within the third variable region of the molecule. Both sites are variable, although the first straddles a cysteine residue (amino acid position 307) which is conserved in all strains of the virus.
The fifth epitope (amino acids 401 to 415) lies in the fourth variable region which shows evidence of duplication over short stretches of amino acids and includes putative glycosylation sites (Sauermann et al., 1990) . It contains two sites which both show variation between strains of HIV-1.
The sequestered epitopes may play a role in the pathogenesis of HIV-1 infection and the following hypothesis is offered as a basis for further work. It is envisaged that following infection the host develops antibodies which can neutralize the virus. A population of viruses then arises which has a carbohydrate molecule masking the neutralizing epitope. Antibody to the original virus population may either be unable to bind to the variant virus or, alternatively, may bind to but not neutralize the virus. In the latter case, the virus will be primed to enter cells via antibody or complement receptors, in particular into cells of the monocyte/ macrophage lineage. This suggestion offers an explanation for the observation that the same serum can neutralize one strain of HIV-1 and enhance infection with a second isolate (Homsy et al., 1988) . After several cycles of infection within a single host, viruses may become totally resistant to neutralization and also show a shift in cellular tropism towards monocytes and macrophages. Viruses with these properties have been isolated from brain macrophages of AIDS patients (ChengMayer & Levy, 1988) .
Sequestered epitopes have previously been invoked as a stratagem by which lentiviruses can evade the host's immune response (Narayan et al., 1988) . There can be no doubt that the addition of a carbohydrate molecule can block antibody binding to an epitope and confer neutralization-resisting properties on a virus, at least in the case of influenza virus (Skehel et al., 1984) . There are two further observations which indicate that these epitopes may be relevant in the progression of HIV-1 infection. Firstly, shifts in the number and position of putative glycosylation sites within the hypervariable region on the N-terminal flank of the CD4-binding region are seen with viruses isolated at different time points from the same patient . Secondly, three of the sequestered epitopes are situated on the N-terminal flanks of the neutralization epitopes which have so far been reported. Although a lack of correlation between in vitro neutralization and in vivo -protection was observed by early investigators (Prince et al., 1988) , more recently in vivo protection has been shown to correlate with the titre of antibodies to the V3/GPGR loop, which is considered to be the immunodominant neutralizing epitope (Berman et al., 1990) . Antibodies to the second variable region of HIV-1 gp 120 and the CD4-binding region have also been reported to have neutralizing properties (Sun et al., 1989; Neurath et al., 1990 ). These observations have been confirmed in unpublished studies from our own laboratory. The regions of gpl20 which are reported to be neutralization epitopes do not themselves contain putative glycosylation sites. Nevertheless, it is possible that gpl20 is folded so that these epitopes are shielded by carbohydrate at other sites in the molecule. Three observations support this concept. Firstly, the regions corresponding to the four N-terminal sequestered epitopes determine, together with the V3/GPGR loop, the ability of the molecule to interact with the transmembrane protein (Kowalski et al., 1987) and the infectivity of the virus (Willey et al., 1989) . These regions may therefore be in close proximity in the native molecule. Secondly, variant viruses which are able to resist neutralization by antibody directed against the V3/GPGR loop appear to have mutations which do not affect the antibody contact residues (Willey et al., 1989; McKeating et al., 1989; Nara et al., 1990) . Thirdly, epitopes without putative glycosylation sites are shielded in glycosylated molecules. For example, antibodies raised to peptide env 7, whose sequence does not contain a putative glycosylation site, bind to unglycosylated but not to glycosylated gpl20 molecules. Antibodies are present in sera from HIV-l-infected patients against epitopes which contain variable putative glycosylation sites. Two of these regions (amino acids 161 to 185 and 331 to 355) contain two sites within seven to 10 amino acid residues of each other and a third (amino acids 231 to 255) contains a single site in HIV-SF2. A second site seven residues distant, which is present in other strains of HIV-1, has been lost following a single amino acid substitution (lysine at position 247). The region between animo acids 161 and 185 has been described above (third epitope). The region between amino acids 231 and 255 has a sequence which is conserved between HIV-1 strains and the region between amino acids 331 and 355 lies on the C-terminal flank of the V3/GPGR loop of gp120. As far as antibodies to the most variable sequestered epitopes are concerned, it is probably unreasonable to expect them to be present in the sera of patients infected with heterologous viruses. Indeed, it is surprising that antibodies binding to peptides representing the V3/GPGR loop of HIV-SF2, which is considered to induce type-specific neutralizing antibodies, are present in Cambridge patients. Group-specific neutralizing sera (Weiss et al., 1986) may therefore consist of a mixture of antibodies, each representing a different virus isolate, rather than antibodies recognizing an epitope shared by different virus strains. The general pattern of binding follows that reported for the C-terminal part of gpl20 (Mathiesen et al., 1989) and includes antibodies to the previously described immunodominant epitope equivalent to peptide env 51 (Palker et al., 1987) .
It will be important to establish whether patients produce antibodies to the most variable sequestered epitopes during infection or vaccination, and to determine if such antibodies influence the growth characteristics and range of target cells of variant viruses within the host. Such studies will require the antigens used in laboratory studies to be homologous to the virus infecting the host. The neutralizing properties of the antipeptide sera are currently under investigation.
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